If you're weighing what to do with your Roche Holding shares, or wondering if now could be the right time to act, you're definitely not alone. The stock has been quietly delivering some intriguing signals. In the past month, Roche is up an impressive 9.7%, contributing to a nearly 13.1% gain year-to-date. Even over the past year, the stock has delivered an 11.2% return, reminding investors of its staying power. Admittedly, its longer-term three-year figure sits at -1.8%, reflecting some industry-wide headwinds and recent uncertainty, but the five-year return of 9.9% shows resilience is still in the company’s DNA.

It is hard to ignore the way Roche’s share price has responded lately to shifting news around the pharmaceutical industry. Recent U.S. policy announcements, such as the evolving debate over drug price negotiations and the potential exclusion of generic drugs from impending tariffs, have injected both optimism and caution into the market. Roche, headquartered in Switzerland, is particularly in the spotlight as Swiss leaders actively engage with U.S. officials to mitigate tariff risks. So, between regulatory headlines and a steady climb in recent weeks, investors sense both new opportunities and a dash of fresh risk.

But at the heart of any investing decision is valuation. By our scorecard, Roche is considered undervalued in 4 out of 6 key checks, landing it a robust value score of 4. That is a strong starting point. Want to see how each valuation approach stacks up? Let us look under the hood. There is a more insightful way to assess value you will not want to miss later on, but first, let us examine the usual suspects.

Why Roche Holding is lagging behind its peers

The Discounted Cash Flow (DCF) model estimates a company's intrinsic value by projecting its future cash flows and discounting them back to today's terms. In Roche Holding's case, this approach uses a two-stage Free Cash Flow to Equity model, translating expected performance into present value in Swiss Francs (CHF).

Currently, Roche generates free cash flow of CHF 14.1 billion. Over the next decade, analyst estimates and further projections suggest this figure could grow to CHF 19.3 billion by 2029. Analyst forecasts are available for the first five years, while Simply Wall St extrapolates remaining years to 2035 and shows a gradual but steady climb in annual free cash flows.

Latest trailing twelve months (LTM) free cash flow: CHF 14.1 billion

Projected 2029 free cash flow: CHF 19.3 billion

DCF-estimated fair value per share: CHF 722.80

Implied discount to current share price: 59.9% undervalued

Based on these calculations, Roche's intrinsic value per share considerably exceeds its current trading price and signals significant undervaluation by this method.

Result: UNDERVALUED

Head to the Valuation section of our Company Report for more details on how we arrive at this Fair Value for Roche Holding.

Our Discounted Cash Flow (DCF) analysis suggests Roche Holding is undervalued by 59.9%. Track this in your watchlist or portfolio, or discover more undervalued stocks.

The Price-to-Earnings (PE) ratio is one of the most widely used valuation tools for profitable companies like Roche Holding. It provides investors with a quick snapshot of how much they are paying today for each franc of earnings, making it especially relevant when evaluating companies with demonstrated profitability.

The level at which a PE ratio is considered normal or fair depends on several factors, including growth expectations and overall risk. Companies with robust future earnings growth or lower perceived risk typically command higher PE ratios, while those facing uncertainties may trade lower.

Roche currently trades on a PE ratio of 26.2x. This is slightly above the pharmaceutical industry average of 24.5x, but well below the average for its immediate peers, which sits at 71.5x. While that could initially look appealing, each benchmark comes with its own context and limitations.

To get a more precise perspective, Simply Wall St calculates a proprietary “Fair Ratio” for Roche at 33.4x. Unlike simple peer or industry averages, this Fair Ratio weighs a wide range of factors specific to Roche, including its expected earnings growth, profit margins, company size, and the risk landscape. This makes it a more tailored and reliable barometer for fair value.

Comparing Roche’s actual PE of 26.2x with its Fair Ratio of 33.4x indicates that the stock is currently undervalued relative to its fundamentals and prospects.

Result: UNDERVALUED

PE ratios tell one story, but what if the real opportunity lies elsewhere? Discover companies where insiders are betting big on explosive growth.

Earlier we mentioned there is an even better way to understand valuation, so let us introduce you to Narratives. A Narrative makes investing personal and powerful by letting you tell the story you believe about a company, then linking that story to the numbers: your own forecasts for revenue, profit margins and a fair value.

On Simply Wall St's Community page, millions of investors use Narratives to map their perspective about Roche (or any company), helping clarify if you think it is time to buy, sell, or hold by directly comparing your Fair Value to the latest share price. Narratives do not just summarize what you believe; they update dynamically as new news or earnings change the outlook, making sure your forecasts and thinking stay relevant with the market.

No longer do you need to just follow the standard models or wait for consensus targets. With Narratives, you can anchor your investing on your convictions, assumptions and up-to-date financial forecasts, all in one place, and all easily shared or challenged by others. For example, some investors' Narratives set Roche's fair value as high as CHF 438.0 thanks to expected medical breakthroughs, while others estimate it as low as CHF 230.0 due to worries about patent risks and competition.

Do you think there's more to the story for Roche Holding? Create your own Narrative to let the Community know!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include ROG.swx.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com